54 batches of Chinese herbal pieces are unqualified. Banlangen accounts for half of the local brands that are not on the list.

A few days ago, the State Food and Drug Administration issued a notice on the disqualification of 54 batches of prepared slices of traditional Chinese medicine, saying that 54 batches of prepared slices of traditional Chinese medicine produced by 46 enterprises were unqualified, and the problem of sulfur dioxide residue was very prominent. It is reported that the relevant regulatory authorities have taken measures such as seizure and seizure, requiring companies to suspend sales and use, recall products, and carry out rectification. According to the reporter's interview, too many "low price wars" and "stragglers" have led to uneven quality of Banlanger on the market. But the public need not panic medication, Guangzhou native Banlangen is not on the list.

28 batches of Radix Isatidis are unqualified

According to the notice of the State Food and Drug Administration, 54 batches of Chinese herbal pieces marked as produced by 46 companies including Shanghai Huaying Pharmaceutical Co., Ltd. are unqualified, of which 28 batches are commonly used Radix Isatidis, and the unqualified items include properties and content. Determination, sulfur dioxide residue, etc.

It is understood that the exposed Banlangen production enterprises include Shanghai Huaying Pharmaceutical Co., Ltd., Anhui Jinfurong traditional Chinese Medicine Co., Ltd., Jiangxi Zhihetang traditional Chinese Medicine Co., Ltd., Shandong Juancheng Zhiyuan traditional Chinese Medicine Co., Ltd., Henan Qingshan Pharmaceutical Co., Ltd., Shaanxi Longli Pharmaceutical Co., Ltd., Ningxia Baicaowang Pharmaceutical Co., Ltd. In addition, 18 batches of Angelica sinensis and 7 batches of Magnolia officinalis showed unqualified inspection. Our reporter noticed that most of the unqualified items also focused on traits, identification, and sulfur dioxide residues.

It is reported that the State Food and Drug Administration has asked local food and drug administration departments to file a case for investigation of illegal acts and make a punishment decision within one month. If it is indeed produced by a labeled production enterprise, the food and drug administration of the relevant province (region or city) shall impose a heavier punishment on the production enterprise. Too many "low price wars" and "stragglers"

Lead to uneven quality of Radix Isatidis

Why isatis root this mass drug will appear a large area of unqualified situation? In this regard, some insiders frankly, the main reason may come from the "low price war" and "stragglers" too much of these two major aspects.

"There are too many manufacturers producing Radix Isatidis, resulting in many of them adopting the 'low price competition strategy' to occupy the market." A person in charge of a Chinese patent medicine company told reporters that two yuan a pack of Radix Isatidis had been sold. "The price is cheaper, but if manufacturers want to make money, they can only find ways to deduct and compress the cost." It said that many ultra-low-priced Radix Isatidis on the market cannot be produced without losing money if the production requirements are strictly followed.

In addition, too many "stragglers" may also lead to uneven quality of Banlangen on the market. "Large enterprises can lay out the whole industrial chain. For example, Banlangen in Baiyunshan has its own GAP planting base of main raw materials, starting from the source to ensure the quality of medicinal materials. However, many small factories producing Banlangen do not have their own planting land and need to purchase medicinal materials from the market. It is difficult to ensure that each batch of medicinal materials meets the quality requirements." The person in charge said.

However, consumers do not have to lose confidence in Banlangen. National policies are supporting the secondary development of traditional Chinese medicine. The research team of Academician Zhong Nanshan is working with Baiyunshan Banlangen to conduct secondary development research. The team further proves the multi-target and multi-channel anti-virus mechanism of Banlangen.

Continue to strictly check Chinese herbal pieces

Last year, the State Administration of Traditional Chinese Medicine issued a notice on the "Special Inspection Plan for the Management of Chinese Herbal Pieces in National Medical Institutions", announcing that it would strictly inspect the quality of Chinese herbal pieces. Subsequently, many provinces have issued a key regulatory catalogue of Chinese medicine tablets. "It can be seen that the quality inspection and tracking of Chinese medicinal materials have become the norm, and the rectification of Chinese medicinal materials will come more violently in the future." Industry analysts believe. It is understood that the policy level attaches great importance to and promote the development of Chinese medicine will bring benefits to the decoction pieces market.

In addition, competition in the formula particle market will continue to intensify this year, and the policy will release positive signals that the industry will move from pilot to formal production and the market will gradually liberalize. (Reporter Tu Duanyu)